Introduction {#S1}
============

Schistosomiasis is one of the most important and severe parasitic diseases in tropical and subtropical areas \[[@R7], [@R19]\]. Worldwide, it affects \>200 million people, with 779 million at risk of infection, and causes the loss of an estimated 4.5 million disability-adjusted life years \[[@R20], [@R28]\]. The final outcome of schistosomiasis is advanced schistosomiasis \[[@R6]\], which can lead to a serious life-threatening condition. Control of transmission of endemic schistosomiasis has been achieved in many areas in China, especially in Jiangsu province from 2011 \[[@R2]\]. Simultaneous treatment and relief of advanced schistosomiasis is well documented \[[@R25]\]. Some cases have occurred in areas where schistosomiasis transmission has been blocked for \>25 years \[[@R3], [@R24]\]. These new cases were named newly developed advanced schistosomiasis (NDAS) by an expert group meeting on schistosomiasis in 2013 and the pathogenesis of NDAS needs further study \[[@R5]\]. Previously, we investigated biochemical indexes and serum proteomic profiles of NDAS, which showed liver fibrosis and some differences in serum \[[@R26]\].

Mass spectrometry can be used to search for biomarkers in the body fluids \[[@R8], [@R9]\] of patients with diseases such as Chagas disease (*Trypanosoma cruzi*) \[[@R16]\] and *Entamoeba histolytica* infection \[[@R15]\], as well as in rheumatoid arthritis screening \[[@R12]\] and cancer research \[[@R1], [@R9], [@R12], [@R27]\]. Mass spectrometry has many advantages, including high sensitivity, short duration from sample collection to diagnosis, potential for high-throughput screening, and a requirement for only small biological samples \[[@R10]\]. We have previously used ClinProTools with matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and magnetic-beads-based weak cation exchange chromatography for enrichment and purification of peptides and proteins \[[@R4], [@R6]\]. Serum peptides differ as early as nine days post-infection in rabbits with *Schistosoma japonicum* infection, and ClinProTools has also been used for early detection of schistosomiasis in sentinel mice.

In the present study, we designed a laboratory assay to measure differentially expressed peptides in serum from NDAS and healthy controls using MALDI-TOF MS and ClinProTools, as shown in [Figure 1](#F1){ref-type="fig"}. The selected peaks were applied to generate proteomic detection pattern (PDP) for NDAS identification.

Figure 1The study design, including sample collection and preparation, MALDI-TOF MS and blind test.

Materials and methods {#S2}
=====================

Patient identification and healthy controls {#S3}
-------------------------------------------

We enrolled patients infected with *S. japonicum* from the Jiangsu provincial census record for detection and treatment, which was compiled in 1977 and checked four times in 1987, 1997, 2008 and 2012. Patients were diagnosed with NDAS according to the sera biochemical index, clinical symptoms and medical history as follows: the serological criterion with hyaluronic acid (HA) \> 100 ng/mL and γ-glutamyl transferase (GGT) \> 50 U/L; network-like changes in the liver and portal vein widening with B-ultrasound scan ([Table 1](#T1){ref-type="table"}); and historical investigation in patients infected with *S. japonicum* before the 1970s and treated with antimony or hexa-chloro-p-xylol four times, with pyquiton at the last chemotherapy. All patients underwent fecal examination 11--45 times from 1976 to 1985 and all results were negative. According to the patients' self-report, their symptoms including pain in the liver appeared and gradually increased from 2008. Thirty NDAS patients aged 55--75 years were selected with the diagnostic criteria, and the healthy control group of thirty age-matched individuals was set as a negative control. A group of an additional fifty NDAS patients and one hundred health controls, following the reporting guideline STARD ([Sup. 1 and Sup. 2](http://Sup.1andSup.2)), were collected for PDP evaluation. All the healthy controls and NDAS patients were evaluated by physical examination at hospital; other diseases including fatty liver, alcohol-induced liver injury, and hepatitis B and C virus infection were excluded.

Table 1Newly developed advanced schistosomiasis (NDAS) patients identified by historical survey, liver B-ultrasound scan and serological examination, 30 healthy people were selected as negative controls.CaseNumberAgeHA (ng/mL)GGT (U/L)B-ultrasoundTime interval between the last chemotherapy and advanced Schistosomiasis determined (years)NDAS3068.49 ± 7.10484.97 ± 458.07168.07 ± 130.35Network-like changes in liver and portal vein widening35.6 ± 5.04Healthy control3068.79 ± 4.1050.67 ± 16.4632.53 ± 7.69No obvious abnormality in the liver--

Table 2Fourteen differential peaks were detected in sera from newly developed advanced schistosomiasis (NDAS) cases when compared to sera from healthy controls using MALDI-TOF-MS and ClinProTools analysis.m/zPeak amplitude*p*Control groupNDAS group5905775.00 ± 425.26265.1 ± 205.10.00317594370.98 ± 44.0122.14 ± 6.530.00317295362.49 ± 31.9928.06 ± 10.80.00317208251.67 ± 37.16173.00 ± 120.970.0054388451.28 ± 29.9528.85 ± 13.220.024194593.94 ± 73.26205.9 ± 142.840.0249428252.79 ± 90.67235.4 ± 245.630.025492498.45 ± 85.4340.57 ± 17.40.02765337116.8 ± 83.7560.43 ± 46.130.04233241108.7 ± 52.5876.59 ± 27.400.04969289165.82 ± 124.8690.63 ± 63.890.04957766297.88 ± 192.94178.61 ± 121.20.04942661119.30 ± 129.4769.27 ± 37.720.0493299176.9 ± 79.6642.4 ± 55.150.0490*Note*. Data are expressed as mean ± *SD*.

Sample collection, HA and GGT detection {#S4}
---------------------------------------

Blood was collected from the arm vein of thirty NDAS patients, left to clot for 30 min at room temperature, and centrifuged at 3000 ×*g* for 10 min at 4 °C to obtain the serum. Sera from thirty healthy controls were used as negative controls. The serological concentration of HA was measured with sandwich ELISA (Elabscience Biotechnology Co. Ltd., Wuhan, China). The standard and unknown samples were added to the plate wells, where the HA-specific antibody was pre-coated. After incubation and washing, biotinylated detection antibody specific for HA and avidin--horseradish peroxidase-conjugate was added to each well. The optical density (OD) was measured immediately at 450 nm after the stop solution was added. The standard curve was drawn with the concentration of standard samples and OD values and the concentrations of HA in the unknown samples were calculated according to the standard curve. GGT was detected with an automatic biochemical analyzer (COBAS C501; Roche). Serum samples from fifty NDAS patients and one hundred healthy controls were collected from a local community health service center in Changshu County, Jiangsu Province, China.

MALDI-TOF MS {#S5}
------------

The study design is shown in [Figure 1](#F1){ref-type="fig"}. The MB-WCX Profiling Kit (Bruker Daltonics, Bremen, Germany) was used for serum peptide enrichment, as described previously \[[@R4]\]. Magnetic beads and serum were mixed in a binding solution, followed by 2 min incubation at room temperature in a standard thin-walled polymerase chain reaction tube. After thorough mixing, washing and elution, the treated sample was transferred to a fresh tube containing 5 μL stabilization buffer. After combination with the matrix of α-cyano-4-hydroxycinnamic acid (Sigma, St. Louis, MO, USA), the mixture was spotted on the polished target (Bruker Daltonics) and detected with MALDI-TOF MS (Autoflex III; Bruker Daltonics). Four MALDI spots of each sample were measured with FlexControl software (Bruker Daltonics). For each spot, 1000 spectra were acquired (200 laser shots at five different spot positions) and all spectra with a signal-to-noise ratio \> 3 were recorded for peptide mass fingerprinting. Mass accuracy was calibrated before measurements, and the detection parameters were set according to the manufacturer's instructions.

Data processing and analysis {#S6}
----------------------------

ClinProTools was used to facilitate the processing and comparison of multiple spectra by automatically defining peak values, normalizing data, subtracting baseline values, and recalibrating the data. Our previous study gave more details \[[@R4]\]. The PDP was established with the differential peaks amplitude to distinguish NDAS and healthy controls with ClinProTools software, as described previously \[[@R4], [@R6]\]. The peak amplitude was shown as mean ± *SD*, and statistical analysis relied on Welch's *t*-test. A *p* value \< 0.05 was considered significant and *p* \< 0.01 highly significant.

Blind test with PDP {#S7}
-------------------

Once the proteomic pattern had been established, the output value for healthy controls was set as 0, that for patients as 1. The additional samples of healthy control and NDAS collected were scored "0" or "1" by the technician without prior knowledge of their true status. The serum samples of fifty NDAS patients and one hundred healthy humans who lived in the same villages were collected and treated with the MB-WCX Profiling Kit, as described above. All spectra captured by MALDI-TOF MS were imported into ClinProTools software for spectrum classification and post-processing, and PDP was used for sample identification. Fifty NDAS patients for the blind test were compared with the thirty NDAS patients for PDP, showing no significant difference (*p* \> 0.05) ([Table 3](#T3){ref-type="table"}).

Table 3Comparison of newly developed advanced schistosomiasis (NDAS) patients between the training group and the verification group.CharacteristicsNo. of cases*p*NADS for PDPNADS for blind-testTotal cases3050Gender0.525 Male1623 Female1427Age0.262HA (0--100 ng/mL)484.97 ± 458.07541.52 ± 482.560.576GGT (3--50 U/L)168.07 ± 130.35142.98 ± 109.190.358

Sensitivity, specificity and reproducibility assay {#S8}
--------------------------------------------------

Sensitivity and specificity were assessed for all the spectra of fifty NDAS patients and one hundred healthy humans with the established PDP. Species specificity was also investigated with twenty sera from *Toxoplasma gondii* infections. The reproducibility and efficiency of MB-WCX bead fractionation were estimated by measuring all samples three times. Each sample was an aliquot stored at −80 °C and was used only once.

Results {#S9}
=======

Serological detection {#S10}
---------------------

HA and GGT were measured in all the patients' sera. The concentrations of HA and GGT were 115.19--1327.8 ng/mL and 53--586 U/L, respectively, and 29--80 ng/mL and 22--48 U/L in healthy controls; the data for the groups is shown in [Table 1](#T1){ref-type="table"}. The reference values of HA and GTT in the sera of healthy controls were 0--100 ng/mL and 0--50 U/L, respectively.

PDP {#S11}
---

Sera from NDAS patients and healthy controls were collected and treated with an MB-WCX Profiling Kit, followed by detection with MALDI-TOF MS and analysis by FlexControl and FlexAnalysis software. The two groups were separated into two clusters with two-dimensional peak distribution analysis, as shown in [Figure 2](#F2){ref-type="fig"}. ClinProTool analysis revealed that 11 peaks with m/z 924, 2661, 2953, 2991, 3241, 3884, 5337, 5905, 5943, 7766 and 9289 were decreased and three peaks with m/z 1945, 2082 and 4282 were increased in the NDAS group, with a significant difference (*p* \< 0.05, *p* \< 0.01) in the amplitudes and peak resolution ratios, as shown in [Table 2](#T2){ref-type="table"}, and which were chosen for PDP establishment. The increased and decreased peaks are shown in [Figures 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"} with the average altitude.

Figure 2Two-dimensional peak distribution with the peptide mass fingerprint from the newly developed advanced schistosomiasis (NDAS) and control groups. The red cross indicates healthy controls and the green circle indicates newly developed advanced schistosomiasis (NDAS) patients.

Figure 3Peptide peaks with features of up-regulation. Compared with the healthy controls (red line), the increased peaks of the newly developed advanced schistosomiasis (NDAS) group are shown as a green line, including three peaks with m/z 1945, 2082 and 4282.

Figure 4Peptide peaks with features of down-regulation. Compared with the healthy controls (red line), the down-regulated peaks of the newly developed advanced schistosomiasis (NDAS) group are shown as a green line, including 11 peaks with m/z 924, 2661, 2953, 2991, 3241, 3884, 5337, 5905, 5943, 7766 and 9289.

Sensitivity, specificity and reproducibility of PDP {#S12}
---------------------------------------------------

The spectra from the other 50 NDAS patients were subjected to PDP and all were successfully verified, which showed 100% sensitivity. One hundred healthy humans who lived in the same villages were also blind tested with PDP for specificity investigation, and 92 were verified correctly. The sera from the patients infected with *T. gondii* were also checked; all sera from patients with *T. gondii* infection were classified "0" (= not infected) using the criteria for NDAS detection established by MS and none of the cases could be diagnosed as NDAS, which indicated 100% species specificity. For the evaluation of reproducibility and efficiency, MB-WCX fractionation was assessed by measuring all samples in triplicate, and all the spectra showed the uniformity for the same sample.

Discussion {#S13}
==========

Hyaluronic acid (HA) is a high molecular weight glycosaminoglycan produced by fibroblasts throughout the body and plays a structural role in the connective tissue matrix. HA is recognized as a non-invasive marker and gold standard of liver fibrosis in chronic liver diseases \[[@R17]\]. According to the census records, all patients infected with *S. japonicum* in Kunshan County received chemotherapy in 1976 \[[@R3]\]. General investigation of the whole population in 1977 and 1983 and physical re-examination in 1979, 1987, 1992 and 1997 revealed that several patients were cured of schistosomiasis, and others were diagnosed with advanced schistosomiasis. The latter had many clinical symptoms such as liver pain, network-like changes in the liver, portal vein widening upon B-ultrasound scanning, and liver fibrosis, which sometimes required surgical treatment. However, some of the patients with apparently cured schistosomiasis reported aggravation of symptoms and they met the criteria for advance schistosomiasis. This indicates that the disease has a longer time of progression and a complicated mechanism of occurrence, and development of the disease is unclear. This new type of schistosomiasis was named NDAS by an expert group \[[@R5]\].

A report on endemic schistosomiasis revealed that the last *Oncomelania hupensis* snail was found in 1983 and eradication of schistosomiasis was achieved in 1989 in Kunshan County \[[@R26]\]. There was no opportunity for re-infection of humans and livestock \[[@R7]\]. Investigation of life history showed that NDAS patients lived in the local area from the 1980s and had no re-exposure to water contaminated with Schistosoma larvae. Hence, NDAS seems not to be related to *S. japonicum* and may be attributed to a different pathogenesis.

Some studies have shown that praziquantel, the primary drug in schistosomiasis treatment \[[@R13], [@R18]\], can only kill adult worms and has no effect on the eggs of *S. japonicum*, which results in pathological damage from the eggs that persist in the liver after insecticidal treatment \[[@R11], [@R14]\]. The soluble egg antigen that is released by the eggs induces liver granuloma and fibrosis, which are the main symptoms in advanced schistosomiasis \[[@R22]\]. However, the eggs could only survive in the mammalian body for about 21 days. The question is how the pathological process can last for the next 10--30 years? The pathogenesis of liver fibrosis without living parasite eggs is still unclear, as is the function of dead eggs in the process.

China has set 2020 as a date for elimination of schistosomiasis \[[@R21]\]. ELISA for antibody detection in serum and microscopy in fecal examination are the main methods to detect *S. japonicum* infection \[[@R23]\]. However, ELISA showed positive results even in treated patients with no eggs found by fecal examination for many years, which led to difficulty in the identification of patients. Fecal examination is a gold standard method for schistosomiasis detection, which can be confirmed once eggs are found in the feces by microscopic detection However, the method has low sensitivity and may lead to false-negative diagnosis, especially with the low infectivity during schistosomiasis elimination.

The PDP established in this study represents a new method to distinguish between NDAS and healthy controls. The results showed that the method worked well with our selected samples, and separate clusters indicated that there were different peak distributions in the two groups. In this study, the fourteen peaks with m/z 924, 2661, 2953, 2991, 3241, 3884, 5337, 5905, 5943, 7766, 9289, 1945, 2082 and 4282 were found in sera with MALDI-TOF MS technology, and were different from the peaks in sera of infected mice from our previous study \[[@R6]\]. Part of the reason could be attributed to the different species and host-parasite interactions. The different peaks in this study could hopefully be used as diagnostic biomarkers, especially m/z 5905, 5943, 2953 and 2082 with *p* \< 0.01 by *t*-tests. Although the unknown origin of the peaks was a technical limitation in our study, the PDP established with these peaks was useful to distinguish the selected samples. The blind test showed 100% sensitivity (50/50), 92% (92/100) specificity and accuracy in detection of the unknown samples, and 100% species specificity using sera associated with *T. gondii* infection. However, it is suggested that the PDP could not be directly used for classification of NDAS and healthy controls on a larger scale at this stage and more samples are needed for further verification. The limitations of our study were the absence of specific biomarkers, and the small sample size, and we should collect more cases in future research. In patients with NDAS, regardless of the pathological and etiological mechanism, the emergence of NDAS also suggested that treatment of liver fibrosis cannot be ignored after chemotherapy.
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###### Supplement 1

Flow diagram of the patient population and reasons for exclusion. NDAS, newly developed advanced schistosomiasis.

###### Supplement 2

Flow diagram of the healthy control population and reasons for exclusion.
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